For research & educational purposes only. This article is a neutral, procedural reference for laboratory / in-vitro research handling — not medical advice or a usage recommendation. These materials are not for human or animal consumption.
What GLP-3 (RT) is
Retatrutide (research code LY3437943, nicknamed 'GLP-3') is a newer lab-made compound being tested in human clinical trials for metabolism. Here it is supplied as an analytical-grade reference material for laboratory research only.
What it does — in plain terms
After you eat, your gut releases hormones that tell your brain 'I'm full' and help your body handle sugar and fat. Most metabolism drugs copy one of those signals — retatrutide is unusual because it copies three at once (GLP-1, GIP, and glucagon). In its human trials, that triple action produced some of the largest body-weight reductions researchers have recorded for this class of compound, which is why it's one of the most closely watched molecules in metabolic science.
Here's where GLP-3 (RT) actually shows up in the published research:
- How the brain senses fullness and controls appetite
- Blood-sugar and insulin handling
- Body-weight change in obesity trials
- Fatty-liver-disease models
Plain-language explanations describe what researchers study — not what any product does for a person, and not medical advice. Every material here is sold for laboratory research use only and is not for human or animal use.
Reconstitution reference
Standard laboratory reconstitution volumes for GLP-3 (RT), from the VNG Reconstitution Sheet. See the full reconstitution guide for the method and concentration math.
| Product | Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|---|
| Retatrutide (GLP-3) | 5 mg | 0.5 mL | 10 mg/mL |
| Retatrutide (GLP-3) | 10 mg | 1 mL | 10 mg/mL |
| Retatrutide (GLP-3) | 20 mg | 2 mL | 10 mg/mL |
| Retatrutide (GLP-3) | 30 mg | 3 mL | 10 mg/mL |
Published research
A selection of peer-reviewed and clinical literature indexed on PubMed. Provided so qualified researchers can locate the primary sources — inclusion here is not a claim about any product or outcome.
- Human clinical studyThe New England journal of medicine · 2023
Retatrutide for obesity — Phase 2 trial
View on PubMed - Peer-reviewed studyBiomolecules · 2025
Retatrutide in obesity pharmacotherapy
View on PubMed - Peer-reviewed studyEuropean journal of pharmacology · 2024
Retatrutide in obesity and diabetes therapy
View on PubMed - Human clinical studyLancet (London, England) · 2023
Retatrutide for type 2 diabetes — Phase 2 trial
View on PubMed - Human clinical studyNature medicine · 2024
Retatrutide for fatty liver disease — Phase 2a trial
View on PubMed - Systematic review of trialsProceedings (Baylor University. Medical Center) · 2025
Retatrutide for obesity — systematic review & meta-analysis
View on PubMed - Systematic review of trialsMetabolism open · 2024
Retatrutide on weight & metabolic markers — meta-analysis
View on PubMed - Human clinical studyDiabetes, obesity & metabolism · 2026
Retatrutide — TRIUMPH clinical trial program
View on PubMed - Human clinical studyThe lancet. Diabetes & endocrinology · 2025
Retatrutide and body composition in type 2 diabetes — Phase 2
View on PubMed - Systematic review of trialsJournal of basic and clinical physiology and pharmacology · 2025
Retatrutide for obesity — review of clinical trials
View on PubMed
References & resources
Related reference materials
VNG Research Team
VNG Labs supplies analytical-grade reference materials with lot-matched Certificates of Analysis. Our write-ups are neutral, source-cited references for qualified and independent researchers.
More from LearnResearch use only. Not for human consumption or veterinary use. Sold exclusively to qualified researchers for in vitro and laboratory research. These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Refrigerate upon receipt. Keep in dark environment.
